MedTrace Logo

LUME BioNIS: a Biomarker Study in Patients With NSCLC

NCT02671422 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2020-09-24

Study results available
· View outcomes & findings →

Summary

At present there are no approved predictive tumour- or serum-derived biomarkers guiding usage of anti-angiogenic therapies in patients with adenocarcinoma of NSCLC.The objective of this NIS is to examine whether genetic/genomic markers (alone or combined with clinical covariates) could be used to predict OS in NSCLC patients eligible for treatment with Vargatef®. The investigations in this study are exploratory in nature and considered to be hypothesis generating. The results from these investigations may help to expand our understanding of the disease and the response to Vargatef®.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-09
Primary Completion
2019-09-03
Completion
2019-09-03

Countries

  • Austria
  • Belgium
  • Denmark
  • Germany
  • Greece
  • Hungary
  • Italy
  • Lithuania
  • Luxembourg
  • Netherlands
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02671422 on ClinicalTrials.gov